Adapted Physical Activity in Patients With Lower Limb Peripheral Arterial Disease

Официальное название

Adapted Physical Activity in Patients With Lower Limb Peripheral Arterial Disease (ACTIV'AO)

Обзор

The prevalence of peripheral arterial disease is 12.2% in France. Intermittent claudication is the most common symtom of this disease. During physical exercise, such as walking, blood oxygen (O2) requirements increase. The development of atherosclerosis in the lower limbs, causes narrowing of the arteries and limits the increase in blood flow required for muscular effort. Patients then experience muscle pain, the intensity of which gradually increases until it forces them to stop. After stopping, the pain subsides and disappears in less than 10 minutes. The location of the pain (calves and/or thighs and/or buttocks) is related to the location of the ischemia (distal in the calf, proximal in the thigh or buttock, or proximo-distal if several locations). This can have different consequences on the biomechanical parameters of walking and muscle activity. To date, the impact of this localization on physical capacity has never been studied. These limitations are very disabling and impact the quality of life of patients. In addition, poor lower limb performance is associated with higher mortality. Reducing symptomatology and improving functional abilities is therefore a major issue in patients with peripheral arterial disease. This can be achieved through the practice of an Adapted Physical Activity, an essential recommendation in the care of patients with peripheral arterial disease. Our main hypothesis is that the physical activity rehabilitation protocol "Activ'AO" will improve the functional capacities of patients with peripheral arterial disease who have followed the program with the localization of ischemia with a greater consideration than in patients in the group following a "standard" APA protocol. Improvements in functional abilities (such as walking) will lead to improvements in quality of life.

Вмешательства

• Другое muscle strengthening targeted on ischemic areas
  muscle strengthening targeted on ischemic areas
• Другое global muscle strenghtening
  global muscle strenghtening

Первичные конечные точки

• Assess efficacity of Adapted Physical Activity with localization of ischemia on maximum walking distance compared to Adapted Physical activity without localization of ischemia [Срок оценки: 12 weeks after inclusion]

Вторичные конечные точки (5)

• Assess efficacity of Adapted Physical Activity with localization of ischemia on walking abilities compared to Adapted Physical activity without localization of ischemia [Срок оценки: 12 weeks after inclusion]
• Assess efficacity of Adapted Physical Activity with localization of ischemia on static balance compared to Adapted Physical activity without localization of ischemia [Срок оценки: 12 weeks after inclusion]
• Assess quality of Life [Срок оценки: At week 12]
• Assess strength capacities [Срок оценки: 12 weeks after inclusion]
• Assess neuromuscular activity [Срок оценки: 12 weeks after inclusion]

Критерии участия

Критерии включения

• Patient with Lower Limb Peripheral Arterial Disease with IPSC < 0.90, arterial stenosis in the lower limbs and intermittent claudication
• No contraindication to physical activity
• Socially insured patients over 18 ;
• Patient who has signed the consent form.

Критерии исключения

• Severe or unstable cardiopulmonary pathologies, contraindicating exercise training
• Unstable angina or myocardial infarction <3 months
• Severe rheumatological pathology of the lower limbs
• Amputee of a lower or upper limb fitted with a device
• Extensive dermatosis of the lower limbs
• Known NYHA grade III or IV heart failure
• Known severe respiratory pathology
• Parkinson's disease, hemiplegia or paraplegia
• Adults subject to enhanced protection, deprived of their liberty by judicial or administrative decision
• Persons unable to consent
• Be in a period of exclusion from other interventional research.
• Any event (injury, surgery, etc.) occurring during the protocol period that could have an impact on results.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Франция · 1 центр

• Centre Hospitalier Du Mans — Le Mans

Идентификаторы

NCT: NCT04800276 · CHM-2019/S18/09

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗